Osteoporosis Treatment in Post-menopausal Women

Taichung Veterans General Hospital

Status and phase: Unknown; Phase 4

Conditions: Depressive Syndrome

Treatments: Drug: Alendronate; Drug: Raloxifene

Study type: Interventional

Funder types: Other

Identifiers

NCT03006003

CE16256A

Details and patient eligibility

About

The study will be conducted to assess the depressive symptoms and related markers in the postmenopausal female after anti-osteoporosis treatment.

Full description

Fracture is one of the important complications in female. Osteoporosis should be treated in postmenopausal female due to high risk of fracture. Recently, there have been many classes of medications developed for preventing bone loss. Raloxifene, an oral form of anti-osteoporosis medication, has been reported to improved central nervous disorders. Therefore, this study is designed to assess the depressive symptoms and related markers in the postmenopausal female after anti-osteoporosis treatment.

Enrollment: 500 estimated patients

Sex: Female

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Postmenopausal female
• Osteoporosis

Exclusion criteria

• Psychological disorders

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

500 participants in 3 patient groups

Raloxifene group

Experimental group

Description:

Raloxifene treatment

Treatment:

Drug: Raloxifene

Comparator group

Active Comparator group

Description:

Alendronate treatment

Treatment:

Drug: Alendronate

Control group

No Intervention group

Description:

To refuse anti-osteoporosis treatment